Cargando…
Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2
Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979866/ https://www.ncbi.nlm.nih.gov/pubmed/33741992 http://dx.doi.org/10.1038/s41541-021-00303-w |
_version_ | 1783667355125022720 |
---|---|
author | Cho, Hansam Jang, Yuyeon Park, Ki-Hoon Choi, Hanul Nowakowska, Aleksandra Lee, Hee-Jung Kim, Minjee Kang, Min-Hee Kim, Jin-Hoi Shin, Ha Youn Oh, Yu-Kyoung Kim, Young Bong |
author_facet | Cho, Hansam Jang, Yuyeon Park, Ki-Hoon Choi, Hanul Nowakowska, Aleksandra Lee, Hee-Jung Kim, Minjee Kang, Min-Hee Kim, Jin-Hoi Shin, Ha Youn Oh, Yu-Kyoung Kim, Young Bong |
author_sort | Cho, Hansam |
collection | PubMed |
description | Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections. |
format | Online Article Text |
id | pubmed-7979866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-79798662021-04-12 Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 Cho, Hansam Jang, Yuyeon Park, Ki-Hoon Choi, Hanul Nowakowska, Aleksandra Lee, Hee-Jung Kim, Minjee Kang, Min-Hee Kim, Jin-Hoi Shin, Ha Youn Oh, Yu-Kyoung Kim, Young Bong NPJ Vaccines Article Here we report a recombinant baculoviral vector-based DNA vaccine system against Middle East respiratory syndrome coronavirus (MERS-CoV) and the severe acute respiratory syndrome coronavirus-2 (SARS-CoV2). A non-replicating recombinant baculovirus expressing the human endogenous retrovirus envelope gene (AcHERV) was constructed as a DNA vaccine vector for gene delivery into human cells. For MERS-CoV vaccine construction, DNA encoding MERS-CoV S-full, S1 subunit, or receptor-binding domain (RBD) was inserted into the genome of AcHERV. For COVID19 vaccine construction, DNA encoding SARS-CoV2 S-full or S1 or a MERS-CoV NTD domain-fused SARS-CoV2 RBD was inserted into the genome of AcHERV. AcHERV-DNA vaccines induce high humoral and cell-mediated immunity in animal models. In challenge tests, twice immunized AcHERV-MERS-S1 and AcHERV-COVID19-S showed complete protection against MERS-CoV and SARS-CoV2, respectively. Unlike AcHERV-MERS vaccines, AcHERV-COVID19-S provided the greatest protection against SARS-CoV2 challenge. These results support the feasibility of AcHERV-MERS or AcHERV-COVID19 vaccines in preventing pandemic spreads of viral infections. Nature Publishing Group UK 2021-03-19 /pmc/articles/PMC7979866/ /pubmed/33741992 http://dx.doi.org/10.1038/s41541-021-00303-w Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Cho, Hansam Jang, Yuyeon Park, Ki-Hoon Choi, Hanul Nowakowska, Aleksandra Lee, Hee-Jung Kim, Minjee Kang, Min-Hee Kim, Jin-Hoi Shin, Ha Youn Oh, Yu-Kyoung Kim, Young Bong Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 |
title | Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 |
title_full | Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 |
title_fullStr | Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 |
title_full_unstemmed | Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 |
title_short | Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2 |
title_sort | human endogenous retrovirus-enveloped baculoviral dna vaccines against mers-cov and sars-cov2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979866/ https://www.ncbi.nlm.nih.gov/pubmed/33741992 http://dx.doi.org/10.1038/s41541-021-00303-w |
work_keys_str_mv | AT chohansam humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT jangyuyeon humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT parkkihoon humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT choihanul humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT nowakowskaaleksandra humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT leeheejung humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT kimminjee humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT kangminhee humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT kimjinhoi humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT shinhayoun humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT ohyukyoung humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 AT kimyoungbong humanendogenousretrovirusenvelopedbaculoviraldnavaccinesagainstmerscovandsarscov2 |